Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Receivables: 2016-2025

Historic Receivables for Akebia Therapeutics (AKBA) over the last 8 years, with Sep 2025 value amounting to $69.3 million.

  • Akebia Therapeutics' Receivables rose 103.80% to $69.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $246.9 million, marking a year-over-year increase of 79.56%. This contributed to the annual value of $36.4 million for FY2024, which is 14.65% down from last year.
  • As of Q3 2025, Akebia Therapeutics' Receivables stood at $69.3 million, which was down 11.38% from $78.2 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Receivables high stood at $138.6 million for Q2 2022, and its period low was $19.1 million during Q1 2023.
  • Its 3-year average for Receivables is $40.6 million, with a median of $34.0 million in 2024.
  • In the last 5 years, Akebia Therapeutics' Receivables soared by 1,787.18% in 2021 and then tumbled by 85.50% in 2023.
  • Akebia Therapeutics' Receivables (Quarterly) stood at $70.7 million in 2021, then tumbled by 40.31% to $42.2 million in 2022, then climbed by 1.04% to $42.6 million in 2023, then declined by 14.65% to $36.4 million in 2024, then surged by 103.80% to $69.3 million in 2025.
  • Its last three reported values are $69.3 million in Q3 2025, $78.2 million for Q2 2025, and $63.1 million during Q1 2025.